PHATHOM PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$221.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- PHATHOM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$221.25M.
- PHATHOM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$334.33M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$221.25M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$334.33M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |